BACKGROUND AND PURPOSE: Estradiol is a sex steroid hormone known to protect the brain against damage related to transient and global cerebral ischemia. In the present study, we leverage an experimental murine model of bilateral carotid artery stenosis (BCAS) to examine the putative effects of estradiol therapy on chronic cerebral hypoperfusion. We hypothesize that long-term estradiol therapy protects against white matter injury and declarative memory deficits associated with chronic cerebral hypoperfusion. METHODS: Adult male C57BL/6J mice underwent either surgical BCAS or sham procedures. Two days after surgery, the mice were given oral estradiol (Sham+E, BCAS+E) or placebo (Sham+P, BCAS+P) treatments daily for 31-34 days. All mice underwent Novel Object Recognition (NOR) testing 31-34 days after the start of oral treatments. Following sacrifice, blood was collected and brains fixed, sliced, and prepared for histological examination of white matter injury and extracellular signal-regulated kinase (ERK) expression. RESULTS: Animals receiving long-term oral estradiol therapy (BCAS-E2 and Sham-E2) had higher plasma estradiol levels than those receiving placebo treatment (BCAS-P and Sham-P). BCAS-E2 mice demonstrated less white matter injury (Klüver-Barrera staining) and performed better on the NOR task compared to BCAS-P mice. ERK expression in the brain was increased in the BCAS compared to sham cohorts. Among the BCAS mice, the BCAS-E2 cohort had a greater number of ERK + cells. CONCLUSION: This study demonstrates a potentially protective role for oral estradiol therapy in the setting of white matter injury and declarative memory deficits secondary to murine chronic cerebral hypoperfusion.
BACKGROUND AND PURPOSE:Estradiol is a sex steroid hormone known to protect the brain against damage related to transient and global cerebral ischemia. In the present study, we leverage an experimental murine model of bilateral carotid artery stenosis (BCAS) to examine the putative effects of estradiol therapy on chronic cerebral hypoperfusion. We hypothesize that long-term estradiol therapy protects against white matter injury and declarative memory deficits associated with chronic cerebral hypoperfusion. METHODS: Adult male C57BL/6J mice underwent either surgical BCAS or sham procedures. Two days after surgery, the mice were given oral estradiol (Sham+E, BCAS+E) or placebo (Sham+P, BCAS+P) treatments daily for 31-34 days. All mice underwent Novel Object Recognition (NOR) testing 31-34 days after the start of oral treatments. Following sacrifice, blood was collected and brains fixed, sliced, and prepared for histological examination of white matter injury and extracellular signal-regulated kinase (ERK) expression. RESULTS: Animals receiving long-term oral estradiol therapy (BCAS-E2 and Sham-E2) had higher plasma estradiol levels than those receiving placebo treatment (BCAS-P and Sham-P). BCAS-E2 mice demonstrated less white matter injury (Klüver-Barrera staining) and performed better on the NOR task compared to BCAS-Pmice. ERK expression in the brain was increased in the BCAS compared to sham cohorts. Among the BCASmice, the BCAS-E2 cohort had a greater number of ERK + cells. CONCLUSION: This study demonstrates a potentially protective role for oral estradiol therapy in the setting of white matter injury and declarative memory deficits secondary to murinechronic cerebral hypoperfusion.
Authors: Louise Lind Schierbeck; Lars Rejnmark; Charlotte Landbo Tofteng; Lis Stilgren; Pia Eiken; Leif Mosekilde; Lars Køber; Jens-Erik Beck Jensen Journal: BMJ Date: 2012-10-09
Authors: Qinghai Liu; Shuhan He; Leonid Groysman; David Shaked; Jonathan Russin; Thomas C Scotton; Steven Cen; William J Mack Journal: PLoS One Date: 2013-12-30 Impact factor: 3.240
Authors: Abigail E Salinero; Lisa S Robison; Olivia J Gannon; David Riccio; Febronia Mansour; Charly Abi-Ghanem; Kristen L Zuloaga Journal: FASEB J Date: 2020-09-16 Impact factor: 5.191
Authors: Nicolás Toro-Urrego; Diego Julián Vesga-Jiménez; María Inés Herrera; Juan Pablo Luaces; Francisco Capani Journal: Curr Neuropharmacol Date: 2019 Impact factor: 7.363
Authors: Qinghai Liu; Kristina Shkirkova; Krista Lamorie-Foote; Michelle Connor; Arati Patel; Robin Babadjouni; Mikko Huuskonen; Axel Montagne; Hans Baertsch; Hongqiao Zhang; Jiu-Chiuan Chen; Wendy J Mack; Brian P Walcott; Berislav V Zlokovic; Constantinos Sioutas; Todd E Morgan; Caleb E Finch; William J Mack Journal: Environ Health Perspect Date: 2021-08-23 Impact factor: 9.031
Authors: Mikko T Huuskonen; Qinghai Liu; Krista Lamorie-Foote; Kristina Shkirkova; Michelle Connor; Arati Patel; Axel Montagne; Hans Baertsch; Constantinos Sioutas; Todd E Morgan; Caleb E Finch; Berislav V Zlokovic; William J Mack Journal: Front Immunol Date: 2021-11-16 Impact factor: 7.561
Authors: Nárlon C Boa Sorte Silva; Oliver Bracko; Amy R Nelson; Fabricio Ferreira de Oliveira; Lisa S Robison; C Elizabeth Shaaban; Atticus H Hainsworth; Brittani R Price Journal: Alzheimers Dement (Amst) Date: 2022-04-27
Authors: Michelle Connor; Krista Lamorie-Foote; Qinghai Liu; Kristina Shkirkova; Hans Baertsch; Constantinos Sioutas; Todd E Morgan; Caleb E Finch; William J Mack Journal: PLoS One Date: 2021-07-02 Impact factor: 3.240